https://orcid.org/0000-0002-8950-0866
Figures
Abstract
Liver inflammation is a common feature of chronic liver disease and is often associated with increased exposure of the liver to lipopolysaccharide (LPS). Kupffer cells (KCs) are macrophages in the liver and produce various cytokines. Activation of KCs through the NLRP3 inflammasome pathway leads to release of proinflammatory cytokines and induces hepatocyte injury and hepatic stellate cell (HSC) activation. Lobeglitazone is a peroxisome proliferator-activated receptor gamma ligand and a type of thiazolidinedione that elicits anti-inflammatory effects. However, there is no clear evidence that it has direct anti-inflammatory effects in the liver. This study showed that lobeglitazone reduces LPS-induced NLPR3 inflammasome activation and production of proinflammatory cytokines in primary KCs and hepatocytes. Cytokines secreted by activated KCs increased hepatocyte inflammation and HSC activation, and lobeglitazone inhibited these responses. In addition, lobeglitazone suppressed liver fibrosis by inhibiting LPS-induced transforming growth factor (TGF)-β secretion and TGF-β-induced CTGF expression. The inhibitory effect of lobeglitazone on inflammasome activation was associated with suppression of liver fibrosis. These results suggest that lobeglitazone may be a treatment option for inflammation and fibrosis in the liver.
Citation: Seo H-Y, Lee S-H, Park JY, Han E, Han S, Hwang JS, et al. (2023) Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver. PLoS ONE 18(8): e0290532. https://doi.org/10.1371/journal.pone.0290532
Editor: Kenji Fujiwara, Kimura Hospital, JAPAN
Received: May 13, 2023; Accepted: August 10, 2023; Published: August 24, 2023
Copyright: © 2023 Seo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF‐2021R1I1A3046593, NRF‐ 2021R1I1A3059150), and was supported by a NRF grant funded by the Korea government (MIST) (NRF‐2022R1A2C1006416). (BK Jang, MK Kim, HY Seo).
Competing interests: The authors have declared that no competing interests exist.
Introduction
Liver inflammation is a common feature of chronic liver disease and is often associated with increased exposure of the liver to lipopolysaccharide (LPS) [1]. An increased level of LPS in the liver causes hepatocyte damage and stimulates liver macrophages [2]. Kupffer cells (KCs) are macrophages in the liver and an essential part of the innate immune system [3]. Alterations in the functional activity of KCs are associated with a variety of liver diseases (e.g., nonalcoholic fatty liver disease and nonalcoholic steatohepatitis) [3–5].
KCs are involved in production of various cytokines such as interleukin 1 (IL1), interleukin 6 (IL6), and tumor necrosis factor (TNF) and regulate inducible nitric oxide synthase (iNOS) levels by releasing reactive oxygen species [6, 7]. Cytokines secreted by activated KCs can directly affect the activation of hepatic stellate cells (HSCs) [8]. These factors can contribute to proliferation and activation of HSCs and extracellular matrix (ECM) synthesis and lead to liver fibrosis [9]. In addition, several cytokines secreted by HSCs induce cell-cell interactions by recruiting KCs and subsequently stimulate KCs to release more inflammatory mediators [10, 11].
The NLRP3 inflammasome is a multiprotein complex containing the adapter protein apoptosis-associated speckle-like protein (ASC) and the serine protease caspase 1 [12–14]. Activation of the inflammasome in macrophages triggers an inflammatory response and amplifies hepatocyte damage through a common pathway of the NLRP3 inflammasome and IL1β, contributing to various liver diseases [15, 16]. Therefore, the inflammasome has been increasingly implicated in severe liver inflammation, fibrosis, and cell death [11, 17].
Lobeglitazone, a type of thiazolidinedione (TZD), is a peroxisome proliferator-activated receptor gamma (PPARγ) ligand used to regulate glucose and lipid metabolism in type 2 diabetes [18]. It reportedly attenuates hepatic steatosis in obese mice by improving insulin resistance and inhibiting lipogenesis-induced liver injury [19, 20]. Lobeglitazone also reportedly has an anti-inflammatory effect [21, 22]. However, reports of its anti-inflammatory effect in the liver are limited, and there is no clear evidence that lobeglitazone ameliorates inflammation through direct effects on the liver.
In this study, we aimed to evaluate the effect of lobeglitazone on NLRP3 inflammasome activation and to explore potential underlying mechanisms.
Materials and methods
Reagents and antibodies
Lobeglitazone was kindly supplied by Chong Kun Dang Pharmaceutical Corporation (Seoul, Republic of Korea). LPS (Escherichia coli 055, B5) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Recombinant human TGF-β (5 ng/mL) was purchased from R&D Systems (Minneapolis, MN, USA). Anti-CTGF (SC365970) and anti-ASC (SC514414) antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). An anti-IL1β antibody (ab9722) was purchased from Abcam (Cambridge, UK). An anticollagen antibody (PA529569) was purchased from Thermo Fisher Scientific (Waltham, MA, USA). Anti-NLRP3 (CS1510), anticleaved caspase 1 (CS89332), anti-GAPDH (CS2118), antitubulin (CS2146), anti-p-STAT3 (CS9138), and anti-STAT3 (CS4904) antibodies, and antirabbit (7074P2) and antimouse (7076P2) secondary antibodies, were purchased from Cell Signaling Technology (Beverly, MA, USA).
Isolation of primary KCs and hepatocytes
All experiments were approved by the institutional animal care and use committee of Keimyung University (KM-2020-26R). All animal procedures were performed in strict accordance with institutional guidelines for animal research. All surgeries were performed under sodium pentobarbital anesthesia, and every effort was made to minimize pain. Mouse KCs and hepatocytes were obtained by perfusion of EGTA solution and collagenase solution (collagenase type I; Worthington Biochemical Corp., Lakewood, NJ, USA) through the portal vein of C57BL/6 mice. The liver was then shaken at 37°C for 20 min, filtered through a 70 μm nylon mesh, and centrifuged at 500 rpm for 5 min to generate a pellet containing hepatocytes and a supernatant containing KCs. Hepatocytes were resuspended in Williams’ medium E (Sigma-Aldrich), cultured in type I collagen-coated dishes (IWAKI Scitech Kiv, Tokyo, Japan) for 1–2 h, and then cultured with medium 199 (Sigma-Aldrich). The hepatocyte pellet and the separated supernatant were centrifuged at 1600 rpm for 10 min, and then the pellet was subjected to OptiPrep (Sigma-Aldrich) density-gradient centrifugation to separate KC. The isolated KC was plated on RPMI 1640 medium (Gibco-BRL, Grand Island, NY, USA) containing 10% fetal bovine serum and incubated for 30 min, then the media was replaced to obtain purified KC. KCs and hepatocytes were pretreated with compounds in 0.5% FBS with or without LPS (1 μg/mL) for 2 h, followed by lobeglitazone (10 μM) for 24 h.
Isolation of primary HSCs
HSCs were isolated from C57BL/6 mice. EGTA, pronase (Roche Diagnostics, Indianapolis, IN, USA), and collagenase (Roche Diagnostics) buffers were sequentially perfused through the inferior vena cava. The liver was shaken in an incubator at 37°C for 20 min, filtered through a 70 μm nylon mesh, and centrifuged at 1625 rpm for 10 min. The pellet containing isolated hepatocytes was mixed with OptiPrep (Sigma-Aldrich) and gently overlaid with a gradient. The sample was centrifuged at 3000 rpm for 17 min at 4°C without braking. HSCs present in the thin white layer at the interface between OptiPrep and Hanks’ Balanced Salt Solution (HBSS) were harvested, washed with HBSS, and plated in DMEM (Gibco-BRL) containing 10% FBS.
Quantitative real-time PCR
Total RNA was isolated from cells using TRIzol reagent (Invitrogen, Waltham, MA, USA), and reverse transcription was performed using a Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). cDNA was diluted and reacted using SYBR Green PCR Master Mix (Roche Diagnostics) and a CFX Connect Real-Time PCR System (Bio-Rad, Richmond, CA, USA). Primer sequences were as follows: NLRP3 (forward) 5′-ATTACCCGCCCGAGAAAGG-3′ and (reverse) 5′-CATGAGTGTGGCTAGATCCAAG-3′, ASC (forward) 5′-TGCAACTGCGAGAAGGCTAT-3′and (reverse) 5′-GTGAGCTCCAAGCCATACGA-3′, caspase 1 (forward) 5′-CGTACACGTCTTGCCCTCAT-3′and (reverse) 5′-AACTTGAGCTCCAACCCTCG-3′, iNOS (forward) 5′-CATGCTACTGGAGGTGGGTG-3′and (reverse) 5′-CATTGATCTCCGTGACAGCC-3′, IL1α (forward) 5′-CAACGTCAAGCAACGGGAAG-3′and (reverse) 5′-AAGGTGCTGATCTGGCTTGG-3′, IL1β (forward) 5′-CTTTCCCGTGGACCTTCCAG-3′and (reverse) 5′-AATGGGAACGTCACACACCA-3′, IL6 (forward) 5′-TTGCCTTCTTGGGACTGATG-3′and (reverse) 5′-CTCATTTCCACGATTTCCCA-3′, TNFα (forward) 5′-ACCGTCAGCCGATTTGCTAT-3′and (reverse) 5′-CCGGACTCCGCAAAGTCTAA-3′, TGF-β (forward) 5’-AAATCAACGGGATCAGCCCC-3′ and (reverse) 5’-GGATCCACTTCCAACCCAGG-3′, and GAPDH (forward) 5′-ACGACCCCTTCATTGACCTC-3′and (reverse) 5′-ATGATGACCCTTTTGGCTCC-3′.
Measurement of cytokine levels
KCs and hepatocytes were seeded, pretreated with LPS for 2 h, and then treated with lobeglitazone for 24 h. The cultures were centrifuged, and cell pellets or supernatants (conditioned media, CM) were stored at –80°C. Levels of iNOS (Abcam) and IL1α, IL1β, IL6, TNF, and TGF-β (R&D Systems, Abingdon, UK) were measured using enzyme-linked immunosorbent assay (ELISA) kits, following the manufacturers’ instructions.
Western blotting
Cells were lysed with RIPA lysis buffer (Thermo Fisher Scientific) containing a cocktail of protease/phosphatase inhibitors (genDEPOT, Katy, TX, USA). Proteins were separated by SDS-PAGE and transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% skim milk prepared in Tris-buffered saline containing 0.1% Tween 20) and incubated with primary antibodies followed by an appropriate horseradish peroxidase-conjugated secondary antibody. Protein expression was detected using the Fusion Solo ChemiDoc system (VILBER LOURMAT, Germany). Protein band intensities were measured using ImageJ software version 1.52a (NIH, Bethesda, MD, USA).
siRNA targeting PPARγ (siPPARγ)
Predesigned siPPARγ was purchased from Santa Cruz Biotechnology. siRNA was transfected using Lipofectamine RNAiMAX reagent (Invitrogen, Carlsbad, CA, USA).
Statistical analysis
Experimental results were statistically analyzed by a one-way analysis of variance with the Bonferroni correction or the two-tailed student’s t test (GraphPad, Prism version 9.5.1). P < 0.05 and P < 0.01 were considered statistically significant. Data are presented as mean ± standard error of the mean (SEM). All experiments were performed at least three times.
Results
Lobeglitazone inhibits secretion of IL1β and other cytokines by LPS-stimulated KCs
To determine whether lobeglitazone inhibits production of proinflammatory cytokines by LPS-stimulated primary KCs, we measured the mRNA levels and secretion of these cytokines. LPS increased mRNA levels and secretion of iNOS, IL6, and TNFα, but these effects were attenuated by lobeglitazone (Fig 1A and 1B). We next determined whether lobeglitazone affects expression and secretion of the inflammasome-specific cytokine IL1β. As expected, mRNA expression and secretion of IL1β were increased in LPS-stimulated KCs, but these effects were attenuated by lobeglitazone (Fig 1A and 1B).
Primary KCs were pretreated with LPS for 2 h and then treated with lobeglitazone for 24 h. (A) Representative real-time RT-PCR analysis of the expression levels of IL1β, iNOS, IL6, and TNFα. Data are mean ± SEM. **P < 0.01 versus the control, ##P < 0.01 versus the LPS-treated group. (B) After 24 h, the media were collected and analyzed by ELISAs. Data are mean ± SEM of three independent measurements. *P < 0.05, **P < 0.01 versus the control; #P < 0.05, ##P < 0.01 versus the LPS-treated group.
Lobeglitazone inhibits NLRP3 inflammasome activation in LPS-stimulated KCs
Next, to verify whether the increased secretion of IL1β upon LPS stimulation contributes to NLRP3 inflammasome activation in KCs, we investigated the effect of lobeglitazone on the NLRP3 inflammasome pathway. In KCs, LPS increased mRNA and protein expression of NLRP3, but these effects were significantly attenuated by lobeglitazone (Fig 2A and 2B). Upregulation and activation of NLRP3 promotes activation of caspase 1 and processing and secretion of IL1β. Lobeglitazone significantly attenuated LPS-induced activation of caspase 1 and upregulation of mature IL1β (Fig 2A and 2B). These results indicate that lobeglitazone inhibits activation of the NLRP3 inflammasome.
Primary KCs were pretreated with LPS for 2 h and then treated with lobeglitazone for 24 h. (A) Representative real-time RT-PCR analysis of the expression levels of NLRP3 and caspase 1. Data are mean ± SEM. **P < 0.01 versus the control, ##P < 0.01 versus the LPS-treated group. (B) Western blot analysis of the effects of lobeglitazone on LPS-induced NLRP3, IL1β, and cleaved caspase 1 expression. Data in the bar graphs are mean ± SEM. *P < 0.05, **P < 0.01 versus the control; #P < 0.05 versus the LPS-treated group.
Lobeglitazone inhibits inflammation induced by KC-secreted cytokines in hepatocytes
Activated KCs secrete cytokines to increase hepatocyte inflammation [23]. Therefore, we investigated whether lobeglitazone inhibits inflammation induced by KC-secreted cytokines in hepatocytes. mRNA levels of IL1β and the proinflammatory cytokines iNOS, IL1α, IL6, and TNFα were increased in hepatocytes cultured in CM of LPS-treated KCs, but these effects were significantly attenuated by lobeglitazone (Fig 3). Therefore, cytokines secreted by KCs upregulate the inflammasome-specific cytokine IL1β and proinflammatory activity, but lobeglitazone attenuates these effects.
Representative real-time RT-PCR analysis of the expression levels of IL1β, IL1α, iNOS, TNFα and IL6 in primary hepatocytes treated with CM of LPS-stimulated KCs. Data are mean ± SEM. **P < 0.01 versus the control; #P < 0.05, ##P < 0.01 versus the LPS-treated group.
Lobeglitazone inhibits NLRP3 inflammasome activation in LPS-stimulated hepatocytes
Next, we examined the effects of lobeglitazone on NLRP3 inflammasome activation in hepatocytes. LPS increased mRNA expression of NLRP3, ASC, and caspase 1, but these effects were significantly attenuated by lobeglitazone (Fig 4A). In addition, the effect of lobeglitazone on secretion of the inflammasome-specific cytokine IL1β was examined. Lobeglitazone decreased LPS-induced secretion of IL1β and expression of NLRP3 and mature IL1β (Fig 4B and 4C). Therefore, lobeglitazone inhibits NLRP3 inflammasome activation in hepatocytes as well as in KCs.
Primary hepatocytes were pretreated with LPS for 2 h and then treated with lobeglitazone for 24 h. (A) Representative real-time RT-PCR analysis of the expression levels of NLRP3, ASC, and caspase 1. Data are mean ± SEM. **P < 0.01 versus the control, ##P < 0.01 versus the LPS-treated group. (B) After 24 h, the media were collected and analyzed by ELISAs. Data are mean ± SEM of three independent measurements. **P < 0.01 versus the control, #P < 0.05, ##P < 0.01 versus the LPS-treated group. (C) Western blot analysis of the effects of lobeglitazone on LPS-induced NLRP3 and IL1β expression. Data in the bar graphs are mean ± SEM. *P < 0.05, **P < 0.01 versus the control, #P < 0.05 versus the LPS-treated group.
Lobeglitazone inhibits inflammation induced by KC-secreted cytokines in HSCs
Several cytokines secreted by KCs directly affect HSC activation, and these cells are therefore central regulators in liver fibrosis [8]. We next investigated whether lobeglitazone inhibits inflammation induced by KC-secreted cytokines in primary HSCs. The mRNA levels of NLRP3, ASC, and caspase 1 were higher in HSCs incubated in CM of LPS-treated KCs than in controls, but these effects were significantly attenuated by lobeglitazone (Fig 5A). In addition, the mRNA levels of alpha smooth muscle actin (αSMA) and collagen were higher in HSCs incubated in CM of LPS-treated KCs than in controls, but these effects were significantly attenuated by lobeglitazone (Fig 5B). Next, we investigated whether lobeglitazone directly affects HSC activation. Protein expression of NLRP3, ASC, and cleaved caspase 1 was increased in activated HSCs and reduced by lobeglitazone. In addition, lobeglitazone decreased protein expression of αSMA and collagen (Fig 5C).
(A, B) Representative real-time RT-PCR analysis of the expression levels of NLRP3, ASC, caspase 1, αSMA, and collagen in primary HSCs treated with CM of LPS-stimulated KCs. Data are mean ± SEM. **P < 0.01 versus the control, ##P < 0.01 versus the LPS-treated group. (C) Western blot analysis of inflammasome and fibrosis markers in cultured HSCs. Primary HSCs were cultured for 7 days in DMEM containing 0.5% FBS with or without lobeglitazone. Data in the bar graphs are mean ± SEM. *P < 0.05 versus the control.
Lobeglitazone inhibits TGF-β, a profibrotic cytokine secreted by KCs and hepatocytes
TGF-β is produced by immune cells such as liver macrophages to directly promote fibrosis [24, 25]. In primary KCs and hepatocytes, LPS increased TGF-β secretion, but this effect was attenuated by lobeglitazone (Fig 6A). Therefore, we further investigated the effect of lobeglitazone on TGF-β-induced expression of the inflammasome-specific cytokine IL1β and the fibrosis marker CTGF. Lobeglitazone attenuated TGF-β-induced IL1β mRNA and protein expression and suppressed TGF-β-induced CTGF expression (Fig 6B and 6C). These results indicate that lobeglitazone inhibits LPS-induced inflammasome activation and TGF-β production, thereby suppressing liver fibrosis.
Primary KCs and hepatocytes were pretreated with LPS for 2 h and then treated with lobeglitazone for 24 h. (A) After 24 h, the media were collected, and TGF-β was measured using an ELISA. Data are mean ± SEM of three independent measurements. *P < 0.05, **P < 0.01 versus the control, #P < 0.05, ##P < 0.01 versus the LPS-treated group. (B) Representative real-time RT-PCR analysis of the expression levels of IL1β in hepatocytes. Data are mean ± SEM. *P < 0.05, **P < 0.01 versus the control, ##P < 0.01 versus the TGF-β-treated group. (C) Western blot analysis of the effects of lobeglitazone on TGF-β-induced CTGF expression. Data in the bar graphs are mean ± SEM. **P < 0.01 versus the control, #P < 0.05 versus the TGF-β-treated group.
Discussion
In this study, lobeglitazone decreased LPS-induced NLPR3 inflammasome activation and proinflammatory cytokine production in primary KCs and hepatocytes. Cytokines secreted by activated KCs increased hepatocyte inflammation and HSC activation, and these responses were inhibited by lobeglitazone. In addition, lobeglitazone inhibited LPS-induced TGF-β secretion and TGF-β-induced CTGF expression, thereby suppressing liver fibrosis.
KCs are liver-resident macrophages accounting for approximately 10% of all hepatic cells and are involved in the pathogenesis of liver inflammation. The inflammatory response in KCs plays an important role in maintaining liver function and homeostasis in response to various stimuli [6, 26]. The NLRP3 inflammasome is expressed in liver hepatocytes, KCs, and HSCs. These cells are activated under certain conditions to release IL1β [8, 27] Of these cells, the NLRP3 inflammasome is reportedly expressed, assembled, and activated mainly in KCs. Activation of KCs through the NLPR3 inflammasome pathway leads to release of proinflammatory cytokines, hepatocyte injury, and HSC activation [10, 28, 29]. In this study, LPS stimulation of kupffer cells induced significantly higher levels of NLRP3 expression and IL1β secretion, activating the NLRP3 inflammasome, and lobeglitazone inhibited the NLRP3 inflammasome and inflammation. In addition, lobeglitazone suppressed the NLRP3 expression in hepatocytes and HSCs. Lobeglitazone is an agonist of PPARγ, which is a nuclear receptor involved in metabolic regulation [30]. PPARγ has been reported to have anti-inflammatory activity by suppressing proinflammatory cytokines or inducing M2/anti-inflammatory polarization of macrophages [28, 31–34]. In this study, LPS increased expression of the anti-inflammatory cytokines IL10 and Arg1 in KCs, and lobeglitazone attenuated these effects. However, the expression levels of IL10 and Arg1 were significantly lower than those of the proinflammatory cytokines IL1β and iNOS (S1 Fig). This finding is thought to be because KCs have a mixed proinflammatory/anti-inflammatory phenotype upon LPS treatment, and it is interpreted that M2/anti-inflammatory polarization does not occur upon lobeglitazone treatment. The PPARγ agonists rosiglitazone and pioglitazone were reported to attenuate NLRP3 inflammasome activation in the kidneys and intestines [35–37]. Therefore, we investigated whether the inhibitory effect of lobeglitazone on the NLRP3 inflammasome in the liver is related to PPARγ. Lobeglitazone still reduced NLRP3 inflammasome activity in cells transfected with siPPARγ (S2 Fig). Therefore, the inhibitory effect of lobeglitazone on the NLRP3 inflammasome is independent of PPARγ, at least in primary hepatocytes, and lobeglitazone directly affects the liver inflammasome. However, animal inflammation models are complex and therefore, additional animal studies are needed to determine how lobeglitazone modulates the inflammasome in vivo.
Inflammatory signaling is a complex process regulated by many different components. LPS upregulates the expression of proinflammatory cytokines such as IL1β, IL6, and TNFα, and upregulated IL6 activates STAT3 pathways [38, 39]. LPS-induced proinflammatory cytokine expression induced STAT3 phosphorylation in KCs and hepatocytes, but these effects were abrogated by lobeglitazone (S3 Fig). This suggests that STAT3 inhibition by lobeglitazone may participate in its anti-inflammatory effect on the liver.
Cytokines secreted by KCs affect production of proinflammatory cytokines in hepatocytes and activate HSCs to induce ECM secretion, which affects liver fibrosis [3, 40]. In this study, several cytokines, such as iNOS and TGF-β, were secreted by LPS-activated KCs, and they increased expression of proinflammatory cytokines in hepatocytes and activated HSCs. However, lobeglitazone suppressed these effects. We examined whether lobeglitazone is directly involved in HSC activation. Lobeglitazone directly inhibits activation of HSCs, but the underlying mechanism requires further study. In addition, lobeglitazone inhibited LPS-induced TGF-β secretion and TGF-β-induced CTGF expression. These results suggest that lobeglitazone has anti-inflammatory and anti-fibrotic effects.
In conclusion, our results show that lobeglitazone decreases LPS-induced NLPR3 inflammasome activation and proinflammatory cytokine production. Additionally, the inhibitory effect of lobeglitazone on inflammasome activation is associated with inhibition of liver fibrosis. These results suggest that lobeglitazone may be a treatment option for inflammation and fibrosis in the liver.
Supporting information
S1 Fig. Effects of lobeglitazone on mRNA expression of IL1β, iNOS, IL10 and Arg1 in KCs.
Representative real-time RT-PCR analysis of the expression levels of IL1β, iNOS, IL10, and Arg1.
https://doi.org/10.1371/journal.pone.0290532.s001
(JPG)
S2 Fig. The inhibitory effect of lobeglitazone on the NLRP3 inflammasome is independent of PPARγ.
(A) Real-time RT-PCR analysis of the effect of PPARγ depletion on iNOS and IL1β expression. Primary KCs were transfected with 50 nM siPPARγ or control siRNA (siCon). *P < 0.05versus the control, #P < ##P < 0.01 versus the LPS-treated siCon, † P < 0.05, †† P < 0.01 versus the LPS-treated siPPARγ. (B) Western blot analysis of the effects of PPARγ depletion on NLRP3 expression. ##P < 0.01 versus the LPS-treated siCon, † P < 0.05 versus the LPS-treated siPPARγ.
https://doi.org/10.1371/journal.pone.0290532.s002
(JPG)
S3 Fig. Lobeglitazone inhibits LPS-induced p-STAT3 expression.
(A, B) Primary KCs and hepatocytes were pretreated with LPS for 2 h and then treated with lobeglitazone for 24 h. Western blot analysis of the effects of lobeglitazone on LPS-induced p-STAT3 expression. Data in the bar graphs are mean ± SEM. **P < 0.01 versus the control, ##P < 0.01 versus the LPS-treated group.
https://doi.org/10.1371/journal.pone.0290532.s003
(JPG)
References
- 1. Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology. 2012;143(5):1158–72. Epub 2012/09/18. pmid:22982943.
- 2. Bjarnason I, Ward K, Peters T. THE LEAKY GUT OF ALCOHOLISM: POSSIBLE ROUTE OF ENTRY FOR TOXIC COMPOUNDS. The Lancet. 1984;323(8370):179–82. pmid:6141332
- 3. Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. Comprehensive Physiology. 2013;3(2):785–97. Epub 2013/05/31. pmid:23720329; PubMed Central PMCID: PMC4748178.
- 4. Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. American journal of physiology Gastrointestinal and liver physiology. 2011;300(5):G697–702. Epub 2011/02/26. pmid:21350183; PubMed Central PMCID: PMC3094133.
- 5. Nagy LE. Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Experimental biology and medicine (Maywood, NJ). 2003;228(8):882–90. Epub 2003/09/12. pmid:12968059.
- 6. Slevin E, Baiocchi L, Wu N, Ekser B, Sato K, Lin E, et al. Kupffer Cells: Inflammation Pathways and Cell-Cell Interactions in Alcohol-Associated Liver Disease. The American Journal of Pathology. 2020;190(11):2185–93. pmid:32919978
- 7. Wan J, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A, Lafdil F, et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: A protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2014;59(1):130–42. pmid:23832548
- 8. Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. Journal of hepatology. 2014;60(5):1090–6. Epub 2014/01/15. pmid:24412603.
- 9. Bieghs V, Trautwein C. The innate immune response during liver inflammation and metabolic disease. Trends in immunology. 2013;34(9):446–52. Epub 2013/05/15. pmid:23668977.
- 10. Koyama Y, Brenner DA. Liver inflammation and fibrosis. The Journal of clinical investigation. 2017;127(1):55–64. Epub 2017/01/04. pmid:28045404; PubMed Central PMCID: PMC5199698.
- 11. Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol. 2014;20(10):2515–32. Epub 2014/03/15. pmid:24627588; PubMed Central PMCID: PMC3949261.
- 12. de Carvalho Ribeiro M, Szabo G. Role of the Inflammasome in Liver Disease. Annual review of pathology. 2022;17:345–65. Epub 2021/11/10. pmid:34752711.
- 13. Jo EK, Kim JK, Shin DM, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cellular & molecular immunology. 2016;13(2):148–59. Epub 2015/11/10. pmid:26549800; PubMed Central PMCID: PMC4786634.
- 14. Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology (Baltimore, Md). 2014;59(3):898–910. Epub 2013/07/03. pmid:23813842; PubMed Central PMCID: PMC4008151.
- 15. Szabo G, Csak T. Inflammasomes in liver diseases. Journal of hepatology. 2012;57(3):642–54. Epub 2012/05/29. pmid:22634126.
- 16. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nature Reviews Immunology. 2013;13(6):397–411. pmid:23702978
- 17. Kaufmann B, Leszczynska A, Reca A, Booshehri LM, Onyuru J, Tan Z, et al. NLRP3 activation in neutrophils induces lethal autoinflammation, liver inflammation, and fibrosis. EMBO reports. 2022:e54446. Epub 2022/10/05. pmid:36194627.
- 18. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor γ in diabetes and metabolism. Trends in Pharmacological Sciences. 2004;25(6):331–6. https://doi.org/10.1016/j.tips.2004.03.012.
- 19. Lee YS, Park JS, Lee DH, Lee D-K, Kwon SW, Lee B-W, et al. The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition. Frontiers in Endocrinology. 2018;9. pmid:30298052
- 20. Bae J, Park T, Kim H, Lee M, Cha BS. Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus. Diabetes & metabolism journal. 2021;45(3):326–36. Epub 2021/04/20. pmid:33866775; PubMed Central PMCID: PMC8164939.
- 21. Kim G, Lee Yh, Yun MR, Lee JY, Shin EG, Lee BW, et al. Effects of lobeglitazone, a novel thiazolidinedione, on adipose tissue remodeling and brown and beige adipose tissue development in db/db mice. International Journal of Obesity. 2018;42(3):542–51. pmid:28895584
- 22. Jeong D, Ko WK, Kim SJ, Han GH, Lee D, Sheen SH, et al. Lobeglitazone Exerts Anti-Inflammatory Effect in Lipopolysaccharide-Induced Bone-Marrow Derived Macrophages. Biomedicines. 2021;9(10). Epub 2021/10/24. pmid:34680549; PubMed Central PMCID: PMC8533245.
- 23. Zhang L, Bansal MB. Role of Kupffer Cells in Driving Hepatic Inflammation and Fibrosis in HIV Infection. Front Immunol. 2020;11:1086. Epub 2020/07/03. pmid:32612603; PubMed Central PMCID: PMC7308419.
- 24. Dooley S, ten Dijke P. TGF-β in progression of liver disease. Cell and tissue research. 2012;347(1):245–56. pmid:22006249
- 25. Sun L, Xiu M, Wang S, Brigstock DR, Li H, Qu L, et al. Lipopolysaccharide enhances TGF-β1 signalling pathway and rat pancreatic fibrosis. Journal of cellular and molecular medicine. 2018;22(4):2346–56. pmid:29424488
- 26. Biozzi G, Stiffel C. The physiopathology of the reticuloendothelial cells of the liver and spleen. Progress in liver diseases. 1965;2:166–91.
- 27. Zeng T, Zhang CL, Xiao M, Yang R, Xie KQ. Critical Roles of Kupffer Cells in the Pathogenesis of Alcoholic Liver Disease: From Basic Science to Clinical Trials. Front Immunol. 2016;7:538. Epub 2016/12/15. pmid:27965666; PubMed Central PMCID: PMC5126119.
- 28. Alegre F, Pelegrin P, Feldstein AE. Inflammasomes in Liver Fibrosis. Seminars in liver disease. 2017;37(2):119–27. Epub 2017/06/01. pmid:28564720.
- 29. Boaru SG, Borkham-Kamphorst E, Tihaa L, Haas U, Weiskirchen R. Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease. Journal of inflammation (London, England). 2012;9(1):49. Epub 2012/11/30. pmid:23192004; PubMed Central PMCID: PMC3599703.
- 30. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nature medicine. 2013;19(5):557–66. pmid:23652116
- 31. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391(6662):82–6. Epub 1998/01/09. pmid:9422509.
- 32. Villapol S. Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation. Cellular and molecular neurobiology. 2018;38(1):121–32. Epub 2017/10/05. pmid:28975471; PubMed Central PMCID: PMC5776063.
- 33. Wang YR, Zhang XN, Meng FG, Zeng T. Targeting macrophage polarization by Nrf2 agonists for treating various xenobiotics-induced toxic responses. Toxicology mechanisms and methods. 2021;31(5):334–42. Epub 2021/02/26. pmid:33627030.
- 34. Luo W, Xu Q, Wang Q, Wu H, Hua J. Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. Sci Rep. 2017;7:44612. Epub 2017/03/17. pmid:28300213; PubMed Central PMCID: PMC5353732.
- 35. Yang CC, Wu CH, Lin TC, Cheng YN, Chang CS, Lee KT, et al. Inhibitory effect of PPARγ on NLRP3 inflammasome activation. Theranostics. 2021;11(5):2424–41. Epub 2021/01/28. pmid:33500734; PubMed Central PMCID: PMC7797672.
- 36. Wang Y, Yu B, Wang L, Yang M, Xia Z, Wei W, et al. Pioglitazone ameliorates glomerular NLRP3 inflammasome activation in apolipoprotein E knockout mice with diabetes mellitus. PloS one. 2017;12(7):e0181248. Epub 2017/07/15. pmid:28708885; PubMed Central PMCID: PMC5510862.
- 37. Hu L, Chen H, Zhang X, Feng Z, Zhang H, Meng Q. Rosiglitazone ameliorates radiation-induced intestinal inflammation in rats by inhibiting NLRP3 inflammasome and TNF-α production. Journal of Radiation Research. 2020;61(6):842–50. pmid:32876675
- 38. Minogue AM, Barrett JP, Lynch MA. LPS-induced release of IL-6 from glia modulates production of IL-1β in a JAK2-dependent manner. Journal of neuroinflammation. 2012;9:126. Epub 2012/06/16. pmid:22697788; PubMed Central PMCID: PMC3418561.
- 39. Markotic A, Flegar D, Grcevic D, Sucur A, Lalic H, Turcic P, et al. LPS-induced inflammation desensitizes hepatocytes to Fas-induced apoptosis through Stat3 activation-The effect can be reversed by ruxolitinib. Journal of cellular and molecular medicine. 2020;24(5):2981–92. Epub 2020/02/06. pmid:32022429; PubMed Central PMCID: PMC7077556.
- 40. Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64(5):830–41. Epub 2015/02/15. pmid:25681399; PubMed Central PMCID: PMC4477794.